Short Summary
Azurity Pharmaceuticals has filed an IPR petition seeking cancellation of claims 1‑3 of Exelixis’s U.S. Pat. 11,298,349 covering oral cabozantinib (L)-malate formulations. The petition alleges anticipation by the earlier Wilson patent and obviousness over Brown, Kubo and Remington, while arguing that discretionary denial factors do not apply.
Detailed Summary
In a petition for inter‑partes review of U.S. Patent 11,298,349, Azurity Pharmaceuticals challenges claims 1‑3 that claim broad oral tablet or capsule formulations of cabozantinib (L)-malate that are essentially free of process by‑products or the impurity 6,7‑dimethoxy‑quinoline‑4‑ol. The challenger asserts two statutory grounds: (1) anticipation under 35 U.S.C. §102 by the earlier Wilson patent, which discloses a species falling within the claimed genus; and (2) obviousness under 35 U.S.C. §103 over Brown in view of Kubo and the Remington textbook, arguing that the combination of known excipients and a one‑step synthetic route would have been obvious. The petition also contends that the claims lack written‑description support for the broad excipient categories and that all Fintiv discretionary factors and the Advanced Bionics test disfavor denial of institution. No settlement or dismissal is indicated, and the proceeding remains at the petition stage awaiting institution.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Azurity Pharmaceuticals, Inc. vs EXELIXIS, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Ericsson Inc. et al.vsPegasus Wireless Innovation LLC
The PTAB denied institution for an IPR concerning Pegasus Wireless Innovation LLC's patent, citing the proximity and significant investment in related district court proceedings. This decision emphasizes efficiency considerations under Fintiv factors when parallel litigation is active.
Dyson Technology Limited et al.vsOmachron Intellectual Property Inc. et al.
Dyson and Omachron settled their inter partes review disputes, leading the PTAB to terminate four IPRs involving Dyson patents. The settlement agreement is treated as confidential business information.
3Shape A/S et al.vsMedit Corporation et al.
3Shape A/S et al. filed an opening petition challenging Medit Corporation's patent (7912257) on grounds of obviousness under 35 U.S.C. § 103. The petitioners argue that the claimed real-time 3D dental scanning method is predictable when combining prior art disclosures from Kopelman and Quadling.
Ericsson Inc et al.vsHeadwater Partners II LLC
Major U.S. carriers and Ericsson settled their IPR dispute over U.S. Patent 9,094,868, leading the PTAB to terminate the proceeding and keep the settlement terms confidential.
Intelligent Wellhead Systems, Inc. et al.vsDowning Wellhead Equipment, LLC et al.
The PTAB instituted PGR on claims 1-78 of the '952 patent after reviewing multiple grounds, including eligibility (§ 101), obviousness (§ 103), and written description/enablement (§ 112). The Board found a likelihood of success for Petitioner despite arguments from Patent Owner regarding prior art limitations.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.